McGill and partners embark on DECIDE-CV program to focus on AI screening for type 2 diabetes mellitus

A three-year partnership between the Research Institute of the McGill University Health Centre, the McGill University Health Centre Foundation, Boehringer Ingelheim Ltd, HOP Tech, and MEDTEQ+ will introduce new ways of screening for type 2 diabetes mellitus (T2DM). The DECIDE-CV program will focus on the development of AI-based technology that will identify T2DM in individuals 35 years of age and older before it causes additional health issues, such as cardiovascular or kidney-related events. “Many people have developed T2DM and don’t know it until a major cardiovascular event occurs,” said Dr Abhinav Sharma, Chief of the DECIDE-CV clinic. “With increased monitoring, doctors can quickly tailor their approach in caring for each patient based on their needs and the information collected – ultimately, improving population-level screening for T2DM in Canada.” News Wire Note: Archived stories may contain dead links or be missing source links.

News Wire | News Wire | News Wire